 | | | | | Efficacy and Safety of 24 Weeks Treatment with Oral TLR8 Agonist Selgantolimod (GS-9688, SLGN) in Virally Suppressed Adult Patients with Chronic Hepatitis B: A Phase 2 Study
| | | | | EASL - The Digital International Liver Congress, 27-29 August 2020
Reported by Jules Levin
Edward Gane,1 P. Rod Dubar,2 Anna E. Brooks,2 Yang Zhao,3 Susanna K. Tan,3 Audrey H. Lau,3 Jenny C. Yang3, Anuj Gaggar,3 Mani Subramanian,3 Shyam Kottilil,4 Lydia Tang4
1Auckland City Hospital, Auckland, New Zealand; 2School of Biological Sciences, Maurice Wilkins Centre, University of Auckland, Auckland, New Zealand; 3Gilead Sciences, Inc., Foster City, CA, USA; 4Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA 
|
|
|
|
